Cargando…
MGMT promoter methylation in Peruvian patients with glioblastoma
PURPOSE: O(6)-methylguanine–DNA methyltransferase (MGMT) promoter methylation predicts the outcome and response to alkylating chemotherapy in glioblastoma. The aim of this study is to evaluate the prevalence of MGMT methylation in Peruvian glioblastoma cases. PATIENTS AND METHODS: We evaluated retro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834313/ https://www.ncbi.nlm.nih.gov/pubmed/29515653 http://dx.doi.org/10.3332/ecancer.2018.812 |
_version_ | 1783303628763693056 |
---|---|
author | Belmar-Lopez, Carolina Castaneda, Carlos A Castillo, Miluska García-Corrochano, Pamela Orrego, Enrique Meléndez, Barbara Casavilca, Sandro Flores, Claudio Orrego, Enrique |
author_facet | Belmar-Lopez, Carolina Castaneda, Carlos A Castillo, Miluska García-Corrochano, Pamela Orrego, Enrique Meléndez, Barbara Casavilca, Sandro Flores, Claudio Orrego, Enrique |
author_sort | Belmar-Lopez, Carolina |
collection | PubMed |
description | PURPOSE: O(6)-methylguanine–DNA methyltransferase (MGMT) promoter methylation predicts the outcome and response to alkylating chemotherapy in glioblastoma. The aim of this study is to evaluate the prevalence of MGMT methylation in Peruvian glioblastoma cases. PATIENTS AND METHODS: We evaluated retrospectively 50 cases of resected glioblastoma during the period 2008–2013 at Instituto Nacional de Enfermedades Neoplasicas in Peru. Samples consisted of paraffin embedded and frozen tumour tissue. MGMT-promoter methylation status and the expression level of MGMT gene were evaluated by methylation-specific PCR and real-time PCR, respectively. RESULTS: Unmethylated, methylated and partially methylated statuses were found in 54%, 20% and 26% of paraffin-embedded samples, respectively. Methylation status was confirmed in the Virgen de la Salud Hospital and frozen samples. There was an association between the status of MGMT-promoter methylation and the level of gene expression (p = 0.001). Methylation was associated with increased progression-free survival (p = 0.002) and overall survival (OS) (p < 0.001). CONCLUSION: MGMT-promoter methylation frequency in Peruvian glioblastoma is similar to that reported in other populations and the detection test has been standardised. |
format | Online Article Text |
id | pubmed-5834313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-58343132018-03-07 MGMT promoter methylation in Peruvian patients with glioblastoma Belmar-Lopez, Carolina Castaneda, Carlos A Castillo, Miluska García-Corrochano, Pamela Orrego, Enrique Meléndez, Barbara Casavilca, Sandro Flores, Claudio Orrego, Enrique Ecancermedicalscience Research PURPOSE: O(6)-methylguanine–DNA methyltransferase (MGMT) promoter methylation predicts the outcome and response to alkylating chemotherapy in glioblastoma. The aim of this study is to evaluate the prevalence of MGMT methylation in Peruvian glioblastoma cases. PATIENTS AND METHODS: We evaluated retrospectively 50 cases of resected glioblastoma during the period 2008–2013 at Instituto Nacional de Enfermedades Neoplasicas in Peru. Samples consisted of paraffin embedded and frozen tumour tissue. MGMT-promoter methylation status and the expression level of MGMT gene were evaluated by methylation-specific PCR and real-time PCR, respectively. RESULTS: Unmethylated, methylated and partially methylated statuses were found in 54%, 20% and 26% of paraffin-embedded samples, respectively. Methylation status was confirmed in the Virgen de la Salud Hospital and frozen samples. There was an association between the status of MGMT-promoter methylation and the level of gene expression (p = 0.001). Methylation was associated with increased progression-free survival (p = 0.002) and overall survival (OS) (p < 0.001). CONCLUSION: MGMT-promoter methylation frequency in Peruvian glioblastoma is similar to that reported in other populations and the detection test has been standardised. Cancer Intelligence 2018-02-14 /pmc/articles/PMC5834313/ /pubmed/29515653 http://dx.doi.org/10.3332/ecancer.2018.812 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Belmar-Lopez, Carolina Castaneda, Carlos A Castillo, Miluska García-Corrochano, Pamela Orrego, Enrique Meléndez, Barbara Casavilca, Sandro Flores, Claudio Orrego, Enrique MGMT promoter methylation in Peruvian patients with glioblastoma |
title | MGMT promoter methylation in Peruvian patients with glioblastoma |
title_full | MGMT promoter methylation in Peruvian patients with glioblastoma |
title_fullStr | MGMT promoter methylation in Peruvian patients with glioblastoma |
title_full_unstemmed | MGMT promoter methylation in Peruvian patients with glioblastoma |
title_short | MGMT promoter methylation in Peruvian patients with glioblastoma |
title_sort | mgmt promoter methylation in peruvian patients with glioblastoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834313/ https://www.ncbi.nlm.nih.gov/pubmed/29515653 http://dx.doi.org/10.3332/ecancer.2018.812 |
work_keys_str_mv | AT belmarlopezcarolina mgmtpromotermethylationinperuvianpatientswithglioblastoma AT castanedacarlosa mgmtpromotermethylationinperuvianpatientswithglioblastoma AT castillomiluska mgmtpromotermethylationinperuvianpatientswithglioblastoma AT garciacorrochanopamela mgmtpromotermethylationinperuvianpatientswithglioblastoma AT orregoenrique mgmtpromotermethylationinperuvianpatientswithglioblastoma AT melendezbarbara mgmtpromotermethylationinperuvianpatientswithglioblastoma AT casavilcasandro mgmtpromotermethylationinperuvianpatientswithglioblastoma AT floresclaudio mgmtpromotermethylationinperuvianpatientswithglioblastoma AT orregoenrique mgmtpromotermethylationinperuvianpatientswithglioblastoma |